广东股票配资开户流程详解欧方IPI调查结果并不公允

　　声明 | 欧盟中国商会反对欧委会IPI下排除中企参与医疗器械公共采购

　　来源：CCCEU

　　欧盟中国商会反对欧委会在IPI下排除中企参与欧盟医疗器械公共采购

　　2025年6月20日，比利时布鲁塞尔

　　6月20日，欧委会宣布在《国际采购工具》（IPI）首个调查后，排除中企在欧盟参与相关公共采购，并要求中标项目中来自中国的产品及零部件比例不得超过50%。欧盟中国商会对欧方这一单边保护主义做法、欧方公开对中企采取不公平的歧视性措施表示坚决反对。

　　商会认为，欧方IPI调查结果并不公允，其“大部分中方医疗公共采购市场排除或歧视欧盟制造的医疗器械及欧盟供应商”结论不符合实际。此外，中国与欧盟在内的贸易伙伴长期就GPA及公共采购问题保持磋商，双向沟通渠道始终畅通。在此背景下，欧方选择仓促地付诸单边措施，令业界十分失望。

　　欧方通过IPI排除中企出医疗采购公共采购，以及增加本地化要求的做法对中国相关产品以及中国供应商严重的歧视性和排他性措施，我们对欧方这一扭曲公平竞争市场环境的做法表示坚决反对，对其对中欧在医疗领域贸易及投资关系发展所带来的冲击表示严正关切。

　　我们呼吁欧方立即停止这一错误做法，为在欧医疗领域中企提供公平、公正和非歧视性的营商环境。

　　Statement： CCCEU Opposes EU‘s Discriminatory IPI Action Against Chinese Companies

　　June 20， 2025， Brussels

　　On 20 June 2025， the European Commission announced the exclusion of Chinese companies from participating in EU public procurement of medical devices exceeding €5 million， following its investigation under the International Procurement Instrument （IPI）． It also imposed a cap， limiting the share of Chinese-origin products and components in awarded contracts to no more than 50%． The China Chamber of Commerce to the EU （CCCEU） expresses deep dissatisfaction and strongly opposes these unilateral and discriminatory measures taken by the EU．

　　The CCCEU considers the IPI findings neither impartial nor based on objective facts． The claim that most EU products and suppliers face discriminatory treatment in China’s public procurement market does not reflect reality．

　　China and the EU have long maintained exchanges on issues related to the WTO Agreement on Government Procurement （GPA） and public procurement practices． Against this backdrop， the EU’s rushed adoption of unilateral measures is deeply disappointing to the business community．

　　The decision to exclude Chinese firms and impose localisation requirements is a blatant act of discrimination against Chinese products and suppliers in the EU’s medical public procurement sector． It seriously distorts fair competition and undermines the principle of a level playing field．

　　We urge the EU to take steps to reverse this regrettable decision and restore a fair， equitable， and non-discriminatory business environment for Chinese enterprises operating in the EU．

　END